504 related articles for article (PubMed ID: 10359907)
1. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy.
Wiedermann U; Jahn-Schmid B; Bohle B; Repa A; Renz H; Kraft D; Ebner C
J Allergy Clin Immunol; 1999 Jun; 103(6):1202-10. PubMed ID: 10359907
[TBL] [Abstract][Full Text] [Related]
2. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
3. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.
Winkler B; Baier K; Wagner S; Repa A; Eichler HG; Scheiner O; Kraft D; Wiedermann U
Clin Exp Allergy; 2002 Jan; 32(1):30-6. PubMed ID: 12002733
[TBL] [Abstract][Full Text] [Related]
4. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946
[TBL] [Abstract][Full Text] [Related]
5. Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy.
Wiedermann U; Jahn-Schmid B; Repa A; Kraft D; Ebner C
Int Arch Allergy Immunol; 1999; 118(2-4):129-32. PubMed ID: 10224359
[TBL] [Abstract][Full Text] [Related]
6. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice.
Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U
PLoS One; 2012; 7(6):e39409. PubMed ID: 22768077
[TBL] [Abstract][Full Text] [Related]
7. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
Int Immunol; 1999 Oct; 11(10):1717-24. PubMed ID: 10508191
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora.
Repa A; Kozakova H; Hudcovic T; Stepankova R; Hrncir T; Tlaskalova-Hogenova H; Pollak A; Wiedermann U
Immunol Lett; 2008 Apr; 117(1):50-6. PubMed ID: 18241932
[TBL] [Abstract][Full Text] [Related]
9. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen.
Hartl A; Kiesslich J; Weiss R; Bernhaupt A; Mostböck S; Scheiblhofer S; Ebner C; Ferreira F; Thalhamer J
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):107-13. PubMed ID: 9893193
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1.
Bauer L; Bohle B; Jahn-Schmid B; Wiedermann U; Daser A; Renz H; Kraft D; Ebner C
Clin Exp Immunol; 1997 Mar; 107(3):536-41. PubMed ID: 9067529
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen.
Wiedermann U; Jahn-Schmid B; Fritsch R; Bauer L; Renz H; Kraft D; Ebner C
Clin Exp Immunol; 1998 Jan; 111(1):144-51. PubMed ID: 9472674
[TBL] [Abstract][Full Text] [Related]
12. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
13. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
14. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen.
Jahn-Schmid B; Wiedermann U; Bohle B; Repa A; Kraft D; Ebner C
J Allergy Clin Immunol; 1999 Nov; 104(5):1015-23. PubMed ID: 10550747
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen.
Marazuela EG; Rodríguez R; Fernández-García H; García MS; Villalba M; Batanero E
Mol Immunol; 2008 Jan; 45(2):438-45. PubMed ID: 17662454
[TBL] [Abstract][Full Text] [Related]
16. Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12.
Jahn-Schmid B; Siemann U; Zenker A; Bohle B; Messner P; Unger FM; Sleytr UB; Scheiner O; Kraft D; Ebner C
Int Immunol; 1997 Dec; 9(12):1867-74. PubMed ID: 9466314
[TBL] [Abstract][Full Text] [Related]
17. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
18. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.
Winkler B; Bolwig C; Seppälä U; Spangfort MD; Ebner C; Wiedermann U
Immunology; 2003 Nov; 110(3):376-85. PubMed ID: 14632666
[TBL] [Abstract][Full Text] [Related]
19. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.
Hufnagl K; Wagner B; Winkler B; Baier K; Hochreiter R; Thalhamer J; Kraft D; Scheiner O; Breiteneder H; Wiedermann U
Clin Exp Immunol; 2003 Aug; 133(2):170-6. PubMed ID: 12869021
[TBL] [Abstract][Full Text] [Related]
20. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
